Form 4: Arcutis Biotherapeutics SVP Matthew Moore Reports Stock Transactions

SVP and Chief Business Officer of Arcutis Biotherapeutics, Matthew Moore, reports acquisition and disposal of common stock related to vesting of Restricted Stock Units.

Summary

• Matthew Richard Moore, SVP and Chief Business Officer of Arcutis Biotherapeutics, reported transactions involving the company's common stock.
• On May 1, 2024, Moore acquired 4,166 shares of common stock at $0 related to Restricted Stock Units (RSUs) that vested.
• These RSUs were initially granted on February 22, 2024, and were subject to a performance-based vesting condition satisfied on May 1, 2024.
• The RSUs will vest in twelve equal quarterly installments on the Vesting Commencement Date.
• On May 2, 2024, Moore disposed of 4,681 shares at an average price of $8.7378 to cover tax withholding requirements related to the RSU vesting.
• The sale was executed in multiple trades with prices ranging from $8.47 to $9.07.
• Following these transactions, Moore beneficially owns 145,505 shares of Arcutis Biotherapeutics common stock.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard disclosure of insider trading activity related to compensation.

Industry Context

This filing is a routine disclosure of insider transactions, which are common for executives receiving stock-based compensation. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives, ensuring compliance with SEC regulations.
• Similar filings are made by executives at comparable biotech companies like Amgen, Biogen, and Gilead Sciences when they trade their company's stock.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• The filing provides transparency to shareholders regarding insider trading activities.

Key Dates